Thromboprophylaxis in cancer patients: case studies
Case study 1: When to continue VTE prophylaxis in a cancer patient with CAP?
Case study 1: outcome
Case study 2: is VTE prophylaxis appropriate in ambulatory cancer receiving outpatient chemotherapy?
Case study 2: outcome
Case study 3: when is switching to oral VTE prophylaxis appropriate?
Case study 3: outcome
Case study 4: What are the pro-thrombotic risks of tamoxifen therapy?
Case study 4: outcome
Case study 5: Is it recommended to stop primary prophylaxis following debulking ovarian surgery?
Case study 5: outcome
VTE treatment in cancer patients: case studies
Case study 6: VTE treatment: what to consider for cancer patients with associated pulmonary embolism?
Case study 6: outcome
Case study 7: what is the optimal duration of therapy for cancer-associated thrombosis?
Case study 7: outcome
Case study 8: how to treat incidental VTE in a patient receiving palliative chemotherapy?
Case study 8: outcome
Case study 9: how to approach recurrence of cancer-associated thrombosis?
Case study 9: outcome
Key learning points
What you'll learn
- The extent of the disease burden of VTE in cancer patients.
- Aetiology and clinical risk factors.
- Patient groups in which VTE thromboprophylaxis is indicated.
- Thromboprophylaxis in patients on long-term tamoxifen.
- Key evidence-based considerations when prescribing DOACs and LMWH.
- Optimum duration for treatment of cancer-associated VTE.
- How to manage incidental or clinically unsuspected VTE.
- How to manage recurrent VTE despite anticoagulation.